5 Results
In The U.S., SK Builds A Stronger Tomorrow
SK Inc. becomes second-largest shareholder of the Center for Breakthrough Medicines, a U.S.-based Cell and Gene Therapy (CGT) CDMO, accelerating its growth as a global leader in the field
SK Pharmteco Expands U.S. Capabilities with Controlling Interest in Center for Breakthrough Medicines
SK Ramps Up U.S. Investments With More than $50 Billion Planned
